The last 12 months have seen dramatic falls in fintech and payments valuations, but with the payments sector now a core part of the financial services ecosystem, strategic imperatives will continue to drive deals despite...more
Volatile technology stocks and rising interest rates put the brakes on fintech funding rounds and M&A in 2022. But even though investment activity fell from 2021’s highs, fintech deal volumes have remained well ahead of...more
Welcome to the Akin Gump Global Private Equity/M&A Survey 2021: Opportunities Ahead.
The last 12 months have been hugely challenging for dealmakers around the world but, after an initial period of disruption following...more
2/2/2021
/ Acquisitions ,
Capital Markets ,
Cross-Border ,
Foreign Investment ,
Global Dealmaking ,
Investment Management ,
Market Volatility ,
Mergers ,
Private Equity ,
Private Equity Firms ,
Special Purpose Acquisition Companies (SPACs) ,
Stock Markets
In this episode, Akin Gump international competition and trade partner Davina Garrod and corporate partner Gavin Weir discuss M&A in the U.K., EU, U.S., China and more, its state of health and where it might go in 2020....more
2/28/2020
/ Acquisitions ,
Antitrust Investigations ,
CFIUS ,
China ,
Coronavirus/COVID-19 ,
Cross-Border Transactions ,
EU ,
Foreign Investment ,
Life Sciences ,
Mergers ,
Trade Relations ,
Trump Administration ,
UK ,
UK Brexit ,
US Trade Policies
Medical device and diagnostics companies and laboratories should anticipate significant legal, regulatory and market changes in 2020 that will have a lasting impact on the industry. From revisions to how the government...more
1/8/2020
/ Acquisitions ,
Artificial Intelligence ,
Biotechnology ,
Centers for Medicare & Medicaid Services (CMS) ,
CFIUS ,
Department of Health and Human Services (HHS) ,
Digital Health ,
EU ,
Export Controls ,
Food and Drug Administration (FDA) ,
General Data Protection Regulation (GDPR) ,
Health Insurance Portability and Accountability Act (HIPAA) ,
Innovation ,
Life Sciences ,
Machine Learning ,
Medical Devices ,
Mergers ,
Office of Foreign Assets Control (OFAC) ,
Patent-Eligible Subject Matter ,
Pharmaceutical Industry ,
Popular ,
Section 101 ,
USPTO